CHARLESTOWN, Mass.--(BUSINESS WIRE)--Flatley Discovery Lab, LLC today announced that it has nominated FDL169, an orally available small molecule for the treatment of Cystic Fibrosis, as a clinical candidate and initiated IND-enabling studies. Data from these studies of FDL169 will be presented next week at the 27th Annual North American Cystic Fibrosis Conference, Salt Lake City, Utah, on October 17th.
Help employers find you! Check out all the jobs and post your resume.
